Biodesix (BDSX) Stock Forecast & Price Target

Biodesix is supported by a differentiated lung-disease diagnostics franchise, with a two-pronged MRD strategy spanning both tumor-informed and tumor-naïve ctDNA testing that broadens its addressable market and reinforces long-term growth potential. Its core business is showing strong operating momentum, as 2Q26 revenue rose 34.2% to $26.9M, diagnostic testing climbed 41.6% on 20,900 tests, gross margin improved to 82%, and adjusted EBITDA loss narrowed 56% to $3.2M while operating expenses increased only 7%. The company also benefits from minimal direct competition, expanding PCP adoption, Medicare-supported demand, and enough facility capacity to support growth for the next 2-3 years without significant capex, which together strengthen the case for sustained share gains and improving profitability.

Biodesix is viewed negatively because its revenue remains highly exposed to reimbursement and payor negotiations, with Medicare still representing 21% of total revenue in 2023 and 23% in 2022, and failure to secure in-network commercial contracts could materially pressure growth and earnings. The company also faces concentration and execution risks around its lung cancer tests and GeneStrat NGS, while the preliminary 2027 CLFS rates appear largely immaterial, offering little offset to broader reimbursement uncertainty. In addition, as a small public company with about $55 million of cash, it may have limited flexibility to fund sales expansion, R&D, laboratory growth, and other capital needs while still working toward sustainable profitability.